Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain scans may unlock migraine treatment success

NCT ID NCT06633484

Knowledge-focused Sponsor: Universitätsklinikum Hamburg-Eppendorf Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether brain scans can help predict which people with migraine will respond to a class of drugs called CGRP antibodies. Researchers used MRI to measure brain structure, activity, and blood flow in 219 adults with frequent migraine before and after 12 weeks of treatment. The goal is to find brain-based markers that separate responders from non-responders, which could lead to more personalized migraine care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 219 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2021

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Migraine patients and Healthy controls. The healthy controls where recruited among hospital staff and non-related acquaintances of the patients. All migraine patients enrolled in the study have been treated with CGRP-targeting mABs according to the indications approved by the respective National regulatory bodies(Germany, Spain, Italy).

Ages

25 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Migraine patients * Adults between 25 and 55 years of age of both sexes; * Patients diagnosed with high-frequency migraine (HFM) 8 or more migraine days/month) or CM with or without aura (\>15 headache days migraine/month, of which 8 have migraine characteristics) according to the International Classification of Headache Disorders, 3rd edition, (ICHD-3); * Females had to be postmenopausal for at least one year, surgically sterile or otherwise incapable of pregnancy, or using an acceptable method of birth control. Healthy controls * Adults between 25 and 55 years of age of both sex; * Absence of any past, or first-degree familial history of recurrent primary or secondary headache disorders. Exclusion Criteria: For the clinical population: * Headache on more than 25 days/month in the last 3 months; * Medication overuse according to the ICHD-3 criteria. For the entire study population (migraine and healthy controls) * Presence of any other significant medical condition (neurological disorders, severe psychiatric illness or cardiovascular disease); * Evidence of drug, smoking or alcohol abuse or dependence within 12 months prior to V1, based on medical records or patient self-report. An alcohol consumption \>100g/week will be considered as an abuse; * Pregnant or breastfeeding women; * Women of childbearing potential, defined as all women physiologically capable of becoming pregnant who are not on contraception; * Concomitant use of other migraine preventive drugs that may interfere with the endpoints of the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Migraine are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Migraine

Contacts and locations

Locations

  • IRCCS Mondino Foundation

    Pavia, Italy

  • University Medical Center Hamburg-Eppendorf

    Hamburg, 20246, Germany

  • Vall d'Hebron Institute of Research

    Barcelona, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.